阿帕替尼联合化疗治疗二线治疗失败后晚期胃癌的疗效与安全性分析

来源 :第十三届全国胃癌学术会议 | 被引量 : 0次 | 上传用户:hankeycncn
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  目的 回顾性分析本院晚期胃腺癌二线治疗失败后接受阿帕替尼联合化疗治疗的疗效与安全性。方法 收集本院2015 年12 月至2017 年4 月二线及以上治疗失败后接受阿帕替尼(425mg或500mg/天)联合化疗治疗的胃及胃食管交界腺癌患者资料。
其他文献
Objective To study the effect of Enhanced Recovery After Surgery(ERAS)and standardization antimicrobial prophylaxis on postoperative intestinal function recovery and microbiota in gastric cancer surge
Objective This meta-analysis is aimed to evaluate the feasibility and safety of enhanced recovery after surgery(ERAS)programs in patients undergoing laparoscopy-assisted gastrectomy(LAG)for gastric ca
会议
会议
会议
会议
会议
Objective To investigate the expression pattern and possible function of Rab3IP in proliferation,reveal the involvement of Rab3IP in cell autophagy and illustrate the mechanism of miR-532-3p as regula
Objective To explore the synthesis procedures of Vitamin B12-modified sericinencapsulated PTX micelles,we refer to these micelles as “VB12-sericin-PBLG-PTX”,and explored the(CD320-receptor-mediated)ce
Objective To explore the synthetic method of a nanomicelle(sericin-PBLG-DOX),and the mechanism of reversing cancer drug resistance.